help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramkumar, T.
Right arrow Articles by Adler, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramkumar, T.
Right arrow Articles by Adler, S.

Endocrinology, Vol 136, 536-542, Copyright © 1995 by Endocrine Society


ARTICLES

Differential positive and negative transcriptional regulation by tamoxifen

T Ramkumar and S Adler
Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri 63110-1094.

Tamoxifen, a nonsteroidal antiestrogen and breast cancer chemotherapeutic, exhibits both estrogen agonist and antagonist properties. Rat GC3 cells grown under estrogen-free conditions were analyzed for the expression of model luciferase reporter genes, either positively or negatively regulated by estrogens. Expression assays adding tamoxifen alone or in combination with 17 beta-estradiol were performed to determine agonist or antagonist activities. In rat GC3 cells, tamoxifen acts as an estrogen antagonist for gene activation, but as an agonist for repression. Regulation by tamoxifen is mediated by estrogen receptor (ER), not via nonreceptor tamoxifen effects. Evaluation of human ER shows that although the wild-type receptor behaves similarly to the rat receptor, the Gly400 to Val400 mutant receptor does not. Tamoxifen, an effective agonist for gene repression with rat and wild-type receptor, shows no agonist activity using this mutated Val400 receptor. Yet, 17 beta-estradiol and clomiphene, another mixed agonist/antagonist, are effective agonists for gene repression with all three receptors. In this model system, tamoxifen functions as antagonist or agonist, depending on whether the ER acts to activate or repress its gene target. In other systems regulated by estrogens, functional analyses of ER action might also serve to predict the agonist or antagonist activity of tamoxifen.


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
B. R. Zysow, K. Kauser, R. M. Lawn, and G. M. Rubanyi
Effects of Estrus Cycle, Ovariectomy, and Treatment with Estrogen, Tamoxifen, and Progesterone on Apolipoprotein(a) Gene Expression in Transgenic Mice
Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1741 - 1745.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society